Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923730 | 0.90 | PDE10A (0.53) | PDE10APARP1TLR7KDM4EHTR3A | |
| SCHEMBL6756278 | 0.85 | TLR7 (0.54) | PDE10APARP1TLR7 | |
| SCHEMBL21695757 | 0.82 | PARP1 (0.41) | PDE10APARP1PDE1BTLR7SCN9A | |
| SCHEMBL21348794 | 0.82 | PARP1 (0.41) | PDE10APARP1PDE1BTLR7PDE1A | |
| SCHEMBL7472961 | 0.76 | NPY1R (0.51) | PDE10APARP1HTR3A | |
| SCHEMBL7467348 | 0.73 | PARP1 (0.47) | PDE10APARP1PARP14 | |
| SCHEMBL11923724 | 0.73 | PARP1 (0.46) | PDE10APARP1TLR7HTR3A | |
| SCHEMBL7465623 | 0.72 | NPY1R (0.48) | PDE10APARP1 | |
| SCHEMBL26654603 | 0.72 | PDE10A (0.37) | PDE10APARP1PDE1BTLR7PDE1A | |
| SCHEMBL30665864 | 0.72 | PDE10A (0.37) | PDE10APARP1PDE1BTLR7PDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | PDE10A 165/4885PARP1 3772/4885PDE1B 285/4885 |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | PDE10A 165/4885PARP1 3772/4885PDE1B 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.